CRISPR's Quiet Inflection Point

Gene editing's public narrative has always favored the single dramatic moment — the first approval, the first cure. What's actually happening in 2026 is less cinematic and more consequential: CRISPR has quietly moved from a proof of concept to a real clinical pipeline, spanning blood disorders, heart disease, cancer, and a category of ultra-rare diseases that didn't have a viable path to treatment at all until recently.

The approved treatment is scaling, slowly

Casgevy, the first CRISPR-based medicine ever approved, continues to be the clearest real-world proof that gene editing works outside a trial setting. In its original sickle cell disease and beta thalassemia trials, 16 of 17 sickle cell patients became free of the painful vaso-occlusive crises that define the disease, and 25 of 27 beta thalassemia patients became independent of the regular blood transfusions the condition normally requires. Uptake in 2025 reached 64 patients treated — nearly triple the prior year — and roughly 90% of U.S. patients have secured reimbursement access despite the treatment's $2.2 million price tag. A Phase III trial extending eligibility to children ages 5 to 11 is now underway.

The next wave: Phase III trials nearing the finish line

Intellia's in vivo editing program — which delivers CRISPR components directly into the body via lipid nanoparticles rather than editing cells outside the body first — has dosed more than 450 patients across two global Phase III trials for hereditary transthyretin amyloidosis, with results showing roughly a 90% reduction in the disease-causing protein sustained over three-plus years. That said, the program hit a real setback: a safety pause in October 2025 following a severe adverse event, a reminder that in vivo editing at scale is still working through unresolved risk. Intellia's separate hereditary angioedema program has finished Phase III enrollment, with an FDA filing expected in the second half of 2026 and a possible commercial launch in early 2027.

The FDA's February 2026 guidance permits a single clinical trial "customized for each individual treated as needed" for ultra-rare diseases — a framework built directly on top of a case that took six months from diagnosis to treatment.

Editing techniques beyond classic CRISPR are catching up

Beam Therapeutics' base-editing approach for alpha-1 antitrypsin deficiency showed 90% healthy protein restoration by day 14 in its highest-dose cohort across more than 25 participants, with an accelerated-approval pathway already aligned with the FDA. Prime Medicine, meanwhile, published the first clinical data ever demonstrating efficacy for prime editing in December 2025, in patients with chronic granulomatous disease — a technique often described as writing new genetic code rather than just cutting it, with more precision than first-generation CRISPR.

The ultra-rare disease breakthrough that's reshaping regulation

The most structurally important development of the past year may be the least visible to the public: a personalized in vivo CRISPR therapy developed, FDA-approved, and delivered to a single infant patient with a life-threatening ultra-rare metabolic disorder called CPS1 deficiency — in just six months from diagnosis. That case, published in the New England Journal of Medicine in May 2025, directly catalyzed new FDA guidance issued in February 2026 that allows a single clinical trial framework "customized for each individual treated as needed," provided the genetic cause is identified, the disease course is understood, and clinical improvement can be demonstrated. It's a regulatory shift that could make gene editing viable for hundreds of ultra-rare conditions too small to ever support a traditional trial.

Cardiovascular disease and cancer are next in line

On the cardiovascular side, Verve Therapeutics' PCSK9-editing approach showed 55–59% reductions in LDL cholesterol sustained over two years — strong enough results that Eli Lilly acquired Verve in June 2025, with a modified formulation now in Phase I trials in Canada and the UK. CRISPR Therapeutics' separate ANGPTL3-editing program showed 55% reductions in triglycerides and 49% in LDL, published in November 2025. In oncology, the Innovative Genomics Institute published Nature research demonstrating in vivo CAR-T cell therapy using CRISPR for the first time — generating cancer-fighting immune cells directly inside the body rather than engineering them externally — with clinical trials expected to begin soon. CRISPR Therapeutics has also dosed its first autoimmune patients, with one person with systemic lupus erythematosus achieving remission in an early basket trial.

The headwind nobody's solved yet

None of this progress is happening in a stable funding environment. U.S. biomedical research took a real hit in 2025: NSF funding was cut in half, a 40% cut to the NIH budget was proposed, and more than 7,500 NIH and NSF grants were suspended or cancelled outright. The clinical momentum described above is largely the product of investment decisions made years earlier — whether that pipeline keeps refilling at the same rate is now an open question.